Inhibition of BCL-2 using specific BH3-mimetic inhibitor Venetoclax efficiently induces apoptosis in CLL cells in circulation, and is also promising for other BCL-2 dependent malignancies such as follicular lymphoma and a subset of DLBCL (44–46). The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.